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Drug discovery today includes considerable focus of laboratory
automation and other resources on both combinatorial chemistry
and high-throughput screening, and computational chemistry has
been a part of pharmaceutical research for many years. The real
bene¢t of these technologies is beyond the exploitation of each
individually. Only recently have signi¢cant e¡orts focused on
e¡ectively integrating these and other discovery disciplines to
realize their larger potential. This technical note will describe
one example of these integration e¡orts.
Introduction
Neurogen Corp. is a pharmaceutical company focusing
on central nervous system (CNS) disorders. Several years
ago, it began to develop methodology, now named
` AIDD
sm’ (accelerated intelligent drug discovery), with
the aim of streamlining and optimizing:
. the generation of lead series;
. the exploration and characterization of lead series;
. the optimization of leads; and
. the optimization of clinical development candidates.
AIDD
sm accomplishes this through tight integration (via
intranet deployed informatics) of combinatorial chemis-
try, high-throughput pharmacology and computational
chemistry. AIDD
sm itself is tightly integrated with the
drug-discovery eå ort and especially with medicinal
chemistry itself (® gure 1).
The focus of AIDD
sm is on the ability to enhance greatly
the drug-discovery cycle: synthesis, data generation, data
analysis and modelling and prioritization of both syn-
thesis and screeningÐ thus completing the cycleÐ on
thousands of compounds every 2 weeks. Additionally,
this is accomplished with:
. very small staå resources (20± 25 FTEs);
. the ability to synthesize 400000 samples per year (as
either mixtures or individual samples) with puri® -
cation and quality assessment;
. biological data generation of 300000 samples per
month;
. a cycle time of 2 weeks;
. targeted eæ ciency gains through computational
chemistry and data-mining of 10£ to well over
50£ over random; and
. the ability to prosecute 13± 15 programmes simul-
taneously in the above manner.
Virtual library (￿ gure 2)
The AIDD
sm virtual library is managed by Neurogen’ s
ISLANDS
sm technology, and is a representation of all
compounds that can be made from the existing reactive
fragment database and synthesis protocols database.
Thus, this virtual library is a very speci® c and dynamic
set of compounds that can easily be millions or billions
of molecules in size. The ISLANDS
sm technology mana-
ging the virtual library is key to AIDD
sm virtual screen-
ing processes as well as to work¯ ow operations. The
ISLANDS
sm software makes it possible to de® ne and
register 50000 compounds from the virtual library easily
and quickly (10min). After de® nition and registration,
not only do the compounds exist electronically in data-
bases for use in AIDD
sm, but also ISLANDS
sm has
generated all information required in the synthesis itself.
The reagents required, the synthesis, reaction work-up
and quality control protocols to be used by the synthesis
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191robotics and all tracking information (sample number,
plate number, well locations) have been automatically
generated and speci® ed with no further input from the
user required.
Virtual screening
A key concept of AIDD
sm is the eå ective prioritization of
both synthesis and screening resources through virtual
screening. Proprietary, unattended and continuous mol-
ecular modelling and data-mining strategies termed ` on-
line continuous modelling’ (OLCM) provide models for
virtual screening of both the virtual library and the
archive of actual compounds. These models work in
concert with ISLANDS
sm for virtual screening of the
virtual library.
On-line continuous modelling
From the inception of our work on AIDD
sm, we planned
to perform computational chemistry modelling with a
novel portfolio approach. A portfolio of modelling stra-
tegies could be expected to provide useful models in a
variety of cases when no one strategy could be expected
to perform well in every situation. Compare this with a
stock portfolio where the expectation is that the portfolio
will increase in value with time even though this cannot
be expected of any one particular stock. The AIDD
sm
portfolio of OLCM includes a variety of both chemical
descriptor types and modelling methods. Fuzzy methods
and machine methods have been very eå ective. Both
artici® cal neural networks and recursive partitioning
methodologies are also used routinely in AIDD
sm OLCM
studies.
A core principle of AIDD
sm and OLCM is the prediction,
prioritization and targeting of populations of compounds
instead of individual compounds. This makes it possible
routinely to achieve signi® cant bene® ts by increasing the
probability of activity in each 2-week cycle. Eæ ciency
gains or targeting enhancements seen in AIDD
sm from
this approach are routinely 10£ to more than
50£ enhancement.
Results
AIDD
sm has been applied to over 20 diverse programmes
at Neurogen. In almost every programme, the value of
AIDD
sm has resulted in novel leads that were readily
optimized to signi® cant levels of activity (® gure 3).
For the last few years, Nurogen has been applying
AIDD
sm technology to the optimization of drug-like
properties within projects toward the generation of
development candidates. OLCM models for several of
these drug-like properties provide guidance for optimiza-
tion of chemical series. These eå orts have resulted in
more eæ cient optimization of candidate ADME, toxico-
logical and PK properties such as metabolic half-life,
cytochrome P450 activity and others.
Summary
An overview of the AIDD
sm drug discovery system at
neurogen has been given. Speci® c examples from active
project areas were presented. The importance of integra-
tion of disciplines and of pragmatism in balancing the
individual components of drug discovery was stressed.
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